Methamphetamine Use Disorder

Australian Coalition Calls For Psychedelic Rules Review Following roughly five months since the country’s Therapeutic Goods Administration (TGA) officially enabled the prescription of MDMA and psilocybin-assisted therapies for certain mental health conditions, a new coalition of healthcare...

Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF)’s Phase 1/2 clinical study assessing safety and efficacy of oral psilocybin for the treatment of Methamphetamine Use Disorder (MUD) has enrolled its first subject.  The investigator-initiated trial led by Dr. Christopher...

Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions. Filament To Begin Phase 2 Study On Botanical Psilocybin Drug For Meth Use Disorder Clinical-stage natural psychedelic drug developer Filament Health Corp. (...